Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.

Saad A. Khan,David E. Gerber,Hong Zhu,Randall S. Hughes,Samantha Mannala,Sawsan Rashdan,Jonathan E. Dowell,Kenneth D. Westover,Jessica Saltarski,Kasia Harrah,Laurin L. Priddy,Hak Choy,Robert Timmerman,Rolf A. Brekken,Noah Sorrelle,Puneeth Iyengar

Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.

2020

Saad A. Khan
David E. Gerber
Hong Zhu
Randall S. Hughes
Samantha Mannala
Sawsan Rashdan
Jonathan E. Dowell
Kenneth D. Westover
Jessica Saltarski
Kasia Harrah
Laurin L. Priddy
Hak Choy
Robert Timmerman
Rolf A. Brekken
Noah Sorrelle
Puneeth Iyengar

e21571Background: ALK-targeting drugs and SABR are combined in patients with metastatic cancer, anecdotally yielding clinical benefit. However, the precise impact of the combination and the optimal...

Keywords:

Radiology
Ablative case
SABR volatility model
Adenocarcinoma
Ceritinib
Pathology
Medicine
Lung
Radiation therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations